Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mersana Therapeutics, Inc. (MRSN : NSDQ)

• Company Description    Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. Number of Employees: 169

• Price / Volume Information    Yesterday's Closing Price: $3.12 Daily Weekly Monthly 20 Day Moving Average: 1,277,367 shares Shares Outstanding: 96.99 (millions) Market Capitalization: $302.61 (millions) Beta: 2.37 52 Week High: $15.34 52 Week Low: $2.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.53% -16.21% 12 Week -19.38% -12.52% Year To Date -49.84% -40.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 840 MEMORIAL DRIVE - CAMBRIDGE,MA 02139 USA ph: 617-498-0020 fax: - ir@mersana.com http://www.mersana.com

• General Corporate Information    Officers Anna Protopapas - Chief Executive Officer and President David Mott - Chairman of the Board Brian DeSchuytner - Chief Financial Officer Ashish Mandelia - Vice President Kristen Hege - Director Peer Information Mersana Therapeutics, Inc. (CORR.) Mersana Therapeutics, Inc. (RSPI) Mersana Therapeutics, Inc. (CGXP) Mersana Therapeutics, Inc. (BGEN) Mersana Therapeutics, Inc. (GTBP) Mersana Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59045L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 96.99 Most Recent Split Date: (:1) Beta: 2.37 Market Capitalization: $302.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: - Price / Sales: 146.26 EPS Growth vs. Year Ago Period: -18.00% vs. Previous Quarter: 13.24% Sales Growth vs. Year Ago Period: 18,409.09% vs. Previous Quarter: 18,409.09% ROE 03/31/22 - -119.10 12/31/21 - -101.42 09/30/21 - -77.17 ROA 03/31/22 - -78.07 12/31/21 - -73.52 09/30/21 - -60.42 Current Ratio 03/31/22 - 4.28 12/31/21 - 3.97 09/30/21 - 4.53 Quick Ratio 03/31/22 - 4.28 12/31/21 - 3.97 09/30/21 - 4.53 Operating Margin 03/31/22 - -8,826.73 12/31/21 - -386,500.03 09/30/21 - -348,653.50 Net Margin 03/31/22 - -8,826.73 12/31/21 - -386,500.03 09/30/21 - -348,653.50 Pre-Tax Margin 03/31/22 - -8,826.73 12/31/21 - -395,488.34 09/30/21 - -348,653.50 Book Value 03/31/22 - 1.45 12/31/21 - 1.69 09/30/21 - 2.17 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.18 12/31/21 - 0.20 09/30/21 - 0.03 Debt-to-Capital 03/31/22 - 14.95 12/31/21 - 16.83 09/30/21 - 3.16

Powered by Zacks Investment Research ©